Dr. Alexander Pieper
About Dr. Alexander Pieper
Dr. Alexander Pieper is the Digital Innovation Manager for Strategy & Operations at Bristol Myers Squibb in München, Germany, with a background in neurogenetics and corporate management.
Digital Innovation Manager at Bristol Myers Squibb
Dr. Alexander Pieper currently serves as the Digital Innovation Manager | Strategy & Operations at Bristol Myers Squibb in München, Bayern, Deutschland. In this role, he focuses on refining innovation strategy and implementing structured innovation processes within the company. His work facilitates corporate innovation, aiming to create unique experience journeys for patients, healthcare professionals, and other stakeholders through omnichannel approaches.
Previous Roles in Biotechnology and Medicine
Before joining Bristol Myers Squibb, Dr. Alexander Pieper worked at several organizations in various management roles. He was a Spin-off Manager at Systasy GmbH from 2011 to 2012 in Göttingen. Prior to that, he served as a Project Manager at Targos molecular pathology gmbh from 2010 to 2011. He also spent five years at the Max-Planck-Institute for Experimental Medicine from 2006 to 2011, where he worked on his Promotion in Neurogenetics.
Educational Background in Management and Biology
Dr. Alexander Pieper has a diverse educational background. He earned a Hagener Zertifikatsstudium Management in Unternehmensführung from FernUniversität in Hagen between 2009 and 2010. He also completed a Promotion in Neurogenetics at the Max-Planck-Institute for Experimental Medicine from 2005 to 2010. Additionally, he holds a Dipl. Biol. from The University of Göttingen, which he obtained from 2000 to 2005.
Advocacy and Professional Beliefs
Dr. Alexander Pieper advocates for authenticity in professional settings, encouraging individuals to reveal their true selves rather than adopting a business persona. He supports intrapreneurship, promoting transformation, change, and resource maximization within organizations. His philosophy centers on adding value through appreciation rather than exploitation, an approach he refers to as 'The Silent Revolution.' He is passionate about bridging the gap between startups and big pharma, aiming to create enriching experiences across the healthcare spectrum.